Chouaib Salem, Janji Bassam, Tittarelli Andres, Eggermont Alexander, Thiery Jean Paul
Institut National de la Sante et de la Recherche Medicale (INSERM U753); Institut Federatif de Recherche 54 (IFR54); Institut de cancerologie Gustave Roussy. F-94800 Villejuif, France.
Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Sante), L-1526 Luxembourg City, Luxembourg.
Crit Rev Immunol. 2014;34(2):91-102. doi: 10.1615/critrevimmunol.2014010183.
Since tumor cell plasticity was first shown to be crucial in tumor promotion and immune surveillance evasion, it has become an issue of intense investigation. Several mechanisms are associated with the acquisition of tumor cell plasticity and immune evasion, including loss of epithelial phenotype through epithelial-to-mesenchymal transition (EMT). We discuss recent evidence revealing that tumor cell plasticity may lead to the emergence of immunoresistant variants and how the tumor microenvironment evolves to shape this plasticity. We argue that targeting carcinoma cell plasticity represents a novel strategy to better control the emergence of resistant variants and to ensure more effective cancer therapies. In this context, the design of innovative integrative immunotherapy approaches is warranted.
自从肿瘤细胞可塑性首次被证明在肿瘤进展和免疫监视逃避中起关键作用以来，它已成为一个深入研究的问题。几种机制与肿瘤细胞可塑性的获得和免疫逃避相关，包括通过上皮-间质转化（EMT）导致上皮表型丧失。我们讨论了最近的证据，这些证据揭示了肿瘤细胞可塑性可能导致免疫抗性变体的出现，以及肿瘤微环境如何演变以塑造这种可塑性。我们认为，针对癌细胞可塑性是一种新策略，可更好地控制抗性变体的出现并确保更有效的癌症治疗。在这种背景下，有必要设计创新的综合免疫治疗方法。
